BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting

Article summary

Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients with higher baseline symptom burden Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients with higher baseline symptom burden